Example: Heart Attack

Clinical Trials on Congenital Myasthenic Syndromes

Total 11 results

    • NCT01203592
      Completed
      Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes
      Conditions: Congenital Myasthenic Syndrome
    • NCT02189720
      No longer available
      Expanded Access Study Amifampridine Phosphate in Congenital Myasthenic Syndrome (CMS)
      Conditions: Congenital Myasthenic Syndrome
    • NCT00872950
      Active, not recruiting
      3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
      Conditions: Lambert-Eaton Myasthenic Syndrome; Congenital Myasthenic Syndrome
    • NCT03062631
      Available
      Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome
      Conditions: Congenital Myasthenic Syndrome; Lambert-Eaton Myasthenic Syndrome
    • NCT01474980
      Completed
      Pregnancy Outcomes in Congenital Myasthenie Syndrome
      Conditions: Congenital Myasthenic Syndrome
    • NCT02012933
      No longer available
      3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
      Conditions: Lambert-Eaton Myasthenic Syndrome (LEMS); Congenital Myasthenia (CM)
    • NCT02562066
      Completed
      Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
      Conditions: Myasthenic Syndromes, Congenital
    • NCT00541216
      Unknown status
      Ephedrine for the Treatment of Congenital Myasthenia
      Conditions: Myasthenic Syndromes, Congenital
    • NCT01765140
      No longer available
      Treatment Use of 3,4-Diaminopyridine
      Conditions: Myasthenic Syndromes, Congenital
    • NCT01378546
      No longer available
      Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
      Conditions: Lambert Eaton Myasthenic Syndrome (LEMS)
    • NCT01403402
      Unknown status
      Congenital Muscle Disease Study of Patient and Family Reported Medical Information
      Conditions: Congenital Muscular Dystrophy (Including Unspecified/Undiagnosed); Dystroglycanopathy; Congenital Fiber Type Disproportion; Rigid Spine Muscular Dystrophy; Congenital Myopathy (Including Unspecified/Undiagnosed); Collagen VI CMD (Ullrich CMD, Intermediate, Bethlem Myopathy); Laminin Alpha 2 Related Congenital Muscular Dystrophy; LAMA2-CMD/Merosin Deficient/MDC1A; Walker-Warburg Syndrome; Muscle-Eye-Brain Disease; Fukuyama/Fukutin Related Muscular Dystrophy; Integrin Alpha 7 Deficiency; Integrin Alpha 9 Deficiency; LMNA-CMD/Lamin A/C/Laminopathy; SEPN1-Related Myopathy; Bethlem Myopathy; Actin Aggregation Myopathy; Cap Disease; Central Core Disease; Centronuclear Myopathy; Core Rod Myopathy; Hyaline Body Myopathy; Multiminicore Myopathy; Myotubular Myopathy; Nemaline Myopathy; Tubular Aggregate Myopathy; Zebra Body Myopathy; Reducing Body Myopathy; Spheroid Body Myopathy; LGMD1B (LMNA); LGMD1E (DES); LGMD2G (TCAP); LGMD2H (TRIM32); LGMD2I (FKRP); LGMD2J (TTN); LGMD2K (POMT1); LGMD2M (FKTN); LGMD2N (POMT2); LGMD2O (POMGnT1); LGMD2P (DAG1); LGMD2Q (PLEC1); LGMD2R (DES); LGMD2S (TRAPPC11); LGMD2T (GMPPB); LGMD2U (ISPD); LGMD2V (GAA); Ullrich Congenital Muscular Dystrophy; Titinopathy; Choline Kinase B Receptor; Emery-Dreifuss Muscular Dystrophy; RYR1 Related Myopathy; SYNE1/Nesprin Related Muscular Dystrophy; Telethonin Related Muscular Dystrophy (TCAP/Titin-Cap); Congenital Myasthenic Syndrome; Escobar Syndrome; Myofibrillar Myopathy; Malignant Hyperthermia; Alpha-Dystroglycan Related Muscular Dystrophy (DAG1, DPM1, DPM2, DPM3, FKRP, FKTN); Alpha-Dystroglycan Related Muscular Dystrophy (GAA, ISPD, LARGE, POMT1, POMT2, POMGnT1); Alpha-Dystroglycan Related Muscular Dystrophy (Unspecified/Undiagnosed/Other)
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations